Skip to content
Clinical Trials – home

UMHAT "Medica Ruse" OOD

Verified siteinfo

Bulgaria Ulitsa Riga 35, 7013 Ruse, Bulgaria

  • 4 trials recruiting
  • Arteriosclerosis · Acute haemorrhagic ulcerative colitis · Acute hepatic failure
  • Adults and children

About Specializations

UMHAT "Medica Ruse" OOD in Ruse, Bulgaria specialises in clinical trials of conditions such as Arteriosclerosis, Acute haemorrhagic ulcerative colitis, Acute hepatic failure, Cardiovascular disorder, and other specialisations. This site conducts important research.

Main research areas of the site

Pain Management and Analgesic Research

The medical center is at the forefront of pain management research, focusing on innovative approaches to alleviate postoperative discomfort. The center's work in this field is pivotal in enhancing patient recovery and quality of life following surgical procedures.

  • Postoperative Pain Relief
  • Analgesic Effectiveness
  • Nociceptor Activation

By exploring the efficacy of novel delivery systems such as nasal sprays, the center contributes significantly to the development of more effective and patient-friendly pain relief options.

Orthopedic Surgery Pain Models

Specializing in orthopedic surgery, the center utilizes this area as a model for studying postoperative pain. This specialization allows for targeted research that directly impacts surgical outcomes and patient care in orthopedic settings.

  • Orthopedic Pain Models
  • Surgical Outcome Improvement
  • Patient Care Enhancement

The center's research bridges the gap between theoretical models and practical applications, ensuring that findings are directly translatable to clinical practice.

Visceral Pain and Analgesic Bridging

In the realm of visceral pain, the center is pioneering research that extends the understanding of analgesic effectiveness from nociceptive to visceral pain contexts. This work is crucial for developing comprehensive pain management strategies.

  • Visceral Pain Management
  • Analgesic Bridging Techniques
  • Comprehensive Pain Strategies

By leveraging evidence from existing literature, the center enhances the applicability of its research, ensuring that it addresses a wide spectrum of pain-related challenges.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Ulitsa Riga 357013 RuseBulgaria
Recruiting now
4 trials
Conditions studied
19
Partner status
Verified site

More sites in RuseBulgaria

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

14 clinical trials

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:POLYPEPTIDE CONSISTING OF A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AND AN AMYLIN RECEPTOR AGONIST, CONNECTED BY A LINKER WITH 4 GLYCINE RESIDUES, AND CONNECTED TO A C18 FATTY ACID SIDE CHAIN
  • Sponsor:Novo Nordisk A/S

Study on the Effects of Baxdrostat and Dapagliflozin in Adults with Chronic Kidney Disease and High Blood Pressure

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

A study to evaluate the effectiveness of tenecteplase in patients with acute ischemic stroke who are more than 4.5 hours after their last known well time.

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Tenecteplase
  • Sponsor:Boehringer Ingelheim International GmbH

Study on the Effects of Vidofludimus Calcium (IMU-838) in Patients with Progressive Multiple Sclerosis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Vidofludimus Calcium
  • Sponsor:Immunic AG

Efficacy and Safety of REGN7508, REGN9933, and Rivaroxaban in Adults with Peripheral Artery Disease after Recent Lower‑Extremity Revascularization

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:REGN7508
  • Sponsor:Regeneron Pharmaceuticals Inc.

A study testing cagrilintide and semaglutide for heart safety in people with cardiovascular disease

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Study Comparing AVT16 and Vedolizumab for Adults with Moderate to Severe Ulcerative Colitis

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Alvotech Swiss AG

Arteriosclerosis

Not recruiting

Study on the Effect of Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease Not Adequately Managed by Current Lipid-Lowering Treatments

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Obicetrapib
  • Sponsor:NewAmsterdam Pharma B.V.

Hypertriglyceridaemia+1

Not recruiting

Study of Olezarsen (ISIS 678354) for Patients with High Triglycerides and Heart Disease or Severe High Triglycerides

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:ISIS 678354 sodium salt
  • Sponsor:Ionis Pharmaceuticals Inc.

Embolism venous

Not recruiting

Comparison of SRSD107 and enoxaparin to prevent blood clots in adults undergoing knee replacement surgery

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Enoxaparin Sodium
  • Sponsor:Sirius Therapeutics Inc.

Study on Fentanyl Nasal Spray and Morphine for Managing Postoperative Pain in Patients After Surgery

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Fentanyl Citrate
  • Sponsor:5med GmbH

Urea cycle disorder+3

Not recruiting

Long-Term Safety Study of HepaStem for Patients with Urea Cycle Disorders, Crigler-Najjar Syndrome, and Fibroinflammatory Liver Diseases

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Hhalpc
  • Sponsor:Cellaïon SA
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.